-
1.发明公开公开(公告)号：US20240327379A1
公开(公告)日：2024-10-03
申请号：US18578864
申请日：2022-07-15
申请人： Sandoz AG
IPC分类号： C07D401/12 , A61K31/506 , C07C59/50
CPC分类号： C07D401/12 , A61K31/506 , C07C59/50
摘要： The present invention relates to a mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl) pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one (INN: evobrutinib) and a process of producing the same. Furthermore, the invention relates to a pharmaceutical composition comprising the mandelate form of evobrutinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of multiple sclerosis.
-
公开(公告)号：US11512068B2
公开(公告)日：2022-11-29
申请号：US16652435
申请日：2018-07-27
申请人： Sandoz AG
发明人： Erwin Schreiner , Sven Nerdinger , Gerhard Laus
IPC分类号： C07D401/14
摘要： The invention relates to acid addition salts of ridinilazole and processes for the preparation of ridinilazole using these acid addition salts. In addition, the present invention relates to processes for the preparation of ridinilazole in pure form using acid addition salts of ridinilazole as process intermediates.
-
公开(公告)号：US11273128B1
公开(公告)日：2022-03-15
申请号：US17231118
申请日：2021-04-15
申请人： Sandoz AG
IPC分类号： A61K9/20 , A61K33/08 , A61K31/506 , A61K9/00
摘要： A pharmaceutical formulation is disclosed which includes at least: (1) elagolix sodium, (2) magnesium oxide, and (3) at least one disintegrating agent, such as crospovidone, croscarmellose sodium, sodium starch glycolate, pregelatinized and mixtures thereof. A tablet is also disclosed which includes a tablet core formed from the pharmaceutical formulation. The elagolix sodium tablets of the present disclosure display improved dissolution rates when tested using for example the Tablet Sink Time test. The tablets also exhibit improved storage stability of the elagolix sodium, with a reduction in degradation products during storage.
-
公开(公告)号：US20210395186A1
公开(公告)日：2021-12-23
申请号：US17285653
申请日：2019-10-16
申请人： Sandoz AG
IPC分类号： C07C229/36 , C07C55/02
摘要： The present invention relates to co-crystals comprising levothyroxine and a dicarboxylic acid, preferably L-tartaric acid or oxalic acid, and processes for the preparation thereof. Furthermore, the invention relates to a pharmaceutical composition comprising a co-crystal of the present invention, preferably the co-crystal comprising levothyroxine and L-tartaric acid or oxalic acid, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypothyroidism.
-
公开(公告)号：US20210087175A1
公开(公告)日：2021-03-25
申请号：US16971908
申请日：2019-02-25
申请人： Sandoz AG
发明人： Verena Adamer , Nolwenn Martin , Andrea Thaler , Veronika Werner , Johannes Raneburger , Franz Xaver Schwarz , Igor Legen , Rebeka Jereb
IPC分类号： C07D403/12
摘要： The present invention relates to a crystalline form of darolutamide and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline form of darolutamide, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The present invention also relates to 5 pharmaceutical compositions comprising darolutamide at a high drug load. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of prostate cancer.
-
公开(公告)号：US10919893B2
公开(公告)日：2021-02-16
申请号：US16483477
申请日：2018-02-07
申请人： Sandoz AG
IPC分类号： C07D471/08
摘要： The invention relates to a process for the preparation of avibactam sodium in polymorphic form C comprising the steps (i) providing a mixture comprising avibactam or a salt thereof and a solvent, wherein the mixture has a water content of less than 2% by weight based on the weight of the mixture; (ii) increasing the temperature of the mixture provided in (i) to at least 55° C. and providing a positive pressure; adding a sodium source to the mixture in step (i) and/or (ii) if the form of avibactam provided in (i) is not avibactam sodium; thereby obtaining avibactam sodium in polymorphic form C.
-
公开(公告)号：US10775384B2
公开(公告)日：2020-09-15
申请号：US16073935
申请日：2017-02-01
申请人： Sandoz AG
摘要： The present invention deals with a method for detecting a protein in a protein sample by amplifying and enhancing small differences between proteins contained in the protein sample. In particular, the present invention uses a cascade of enzymatic modification steps to detect and identify a protein in a protein sample by enhancing small differences between the protein and other proteins contained in the protein sample. Further, the present invention provides a method for distinguishing two proteins having substantially identical or similar amino acid sequences but different protein conformations.
-
公开(公告)号：US10703750B2
公开(公告)日：2020-07-07
申请号：US16462358
申请日：2017-12-06
申请人： Sandoz AG
发明人： Christoph Langes , Stefan Reissmann
IPC分类号： C07D471/04
摘要： The present disclosure generally relates to crystalline valbenazine. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline valbenazine, as well of methods of using crystalline valbenazine in the treatment of hyperkinetic disorders, and methods for obtaining such forms.
-
公开(公告)号：US10661264B2
公开(公告)日：2020-05-26
申请号：US16103473
申请日：2018-08-14
发明人： Rainer Hahn , Alois Jungbauer , Alexandru Trefilov
IPC分类号： B01J39/20 , B01J39/04 , C12N9/02 , C07K1/18 , B01J39/26 , B01J41/14 , B01J41/20 , B01J47/04 , B01J39/05 , B01J39/07 , B01J41/05 , B01J41/07 , B01D15/36 , C07K14/435 , C07K16/00
摘要： The present invention provides novel methods of cell disruption and release of biomolecules from a cell. The invention comprises the use of positively and/or negatively charged microparticles comprising ground resin. It is particularly useful for purification of biomolecules from cell culture.
-
公开(公告)号：US20190315744A1
公开(公告)日：2019-10-17
申请号：US16462358
申请日：2017-12-06
申请人： Sandoz AG
发明人： Christoph Langes , Stefan Reissmann
IPC分类号： C07D471/04
摘要： The present disclosure generally relates to crystalline valbenazine. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline valbenazine, as well of methods of using crystalline valbenazine in the treatment of hyperkinetic disorders, and methods for obtaining such forms.
-
-
-
-
-
-
-
-
-
搜索结果
978 条记录 (耗时 0.023 秒)
